AP2016009322A0 - (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors - Google Patents

(2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors

Info

Publication number
AP2016009322A0
AP2016009322A0 AP2016009322A AP2016009322A AP2016009322A0 AP 2016009322 A0 AP2016009322 A0 AP 2016009322A0 AP 2016009322 A AP2016009322 A AP 2016009322A AP 2016009322 A AP2016009322 A AP 2016009322A AP 2016009322 A0 AP2016009322 A0 AP 2016009322A0
Authority
AP
ARIPO
Prior art keywords
oxazepane
carboxamides
phenylethyl
cyano
inhibitors
Prior art date
Application number
AP2016009322A
Other languages
English (en)
Inventor
Hans Roland Lonn
Stephen Connolly
Steven Swallow
Staffan Po Karlsson
Carl-Johan Aurell
John Fritiof Ponten
Kevin James Doyle
De Poel Amanda Jane Van
Graham Peter Jones
David Wyn Watson
Jaqueline Anne Macritchie
Nicholas John Palmer
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52432834&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2016009322(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AP2016009322A0 publication Critical patent/AP2016009322A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/10—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Epoxy Compounds (AREA)
AP2016009322A 2014-01-24 2015-01-23 (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors AP2016009322A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461931090P 2014-01-24 2014-01-24
PCT/GB2015/050155 WO2015110826A1 (en) 2014-01-24 2015-01-23 (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors

Publications (1)

Publication Number Publication Date
AP2016009322A0 true AP2016009322A0 (en) 2016-07-31

Family

ID=52432834

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2016009322A AP2016009322A0 (en) 2014-01-24 2015-01-23 (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors

Country Status (38)

Country Link
US (18) US9522894B2 (enExample)
EP (4) EP4548972A3 (enExample)
JP (7) JP6469711B2 (enExample)
KR (1) KR102417684B1 (enExample)
CN (2) CN105980367B (enExample)
AP (1) AP2016009322A0 (enExample)
AR (1) AR099177A1 (enExample)
AU (4) AU2015208932C1 (enExample)
BR (1) BR112016016224B1 (enExample)
CA (1) CA2935625C (enExample)
CL (1) CL2016001889A1 (enExample)
CR (1) CR20160327A (enExample)
CY (2) CY1120049T1 (enExample)
DK (3) DK3323814T3 (enExample)
DO (1) DOP2016000175A (enExample)
EA (1) EA032794B1 (enExample)
ES (3) ES3018635T3 (enExample)
FI (1) FI3744714T3 (enExample)
HR (3) HRP20180116T1 (enExample)
HU (3) HUE052421T2 (enExample)
IL (3) IL246614B (enExample)
LT (3) LT3097086T (enExample)
MX (1) MX368840B (enExample)
MY (1) MY194850A (enExample)
NO (1) NO2699580T3 (enExample)
NZ (2) NZ734768A (enExample)
PE (1) PE20161218A1 (enExample)
PH (1) PH12016501439A1 (enExample)
PL (3) PL3744714T3 (enExample)
PT (3) PT3744714T (enExample)
RS (3) RS66709B1 (enExample)
SG (2) SG11201606052TA (enExample)
SI (3) SI3744714T1 (enExample)
SM (3) SMT202500137T1 (enExample)
TW (1) TWI690517B (enExample)
UY (1) UY35963A (enExample)
WO (1) WO2015110826A1 (enExample)
ZA (2) ZA201605856B (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2699580T3 (enExample) 2014-01-24 2018-02-24
KR20250107292A (ko) * 2016-07-29 2025-07-11 인스메드 인코포레이티드 기관지확장증을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카르복스아미드
CA3089240A1 (en) * 2018-02-07 2019-08-15 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating anca associated vasculitides
KR102738945B1 (ko) 2018-03-01 2024-12-04 아스트라제네카 에이비이 (2s)-n-｛(1s)-1-시아노-2-[4-(3-메틸-2-옥소-2,3-디하이드로-1,3-벤족사졸-5-일)페닐]에틸｝-1,4-옥사제판-2-카복스아미드를 포함하는 약학 조성물
WO2020018551A1 (en) * 2018-07-17 2020-01-23 Insmed Incorporated Certain (2s)- n-[(1s)-1-cyano-2-phenylethyl]-1,4- oxazepane-2-carboxamides for treating inflammatory bowel disease
AU2019306532A1 (en) * 2018-07-17 2021-03-04 Insmed Incorporated Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating Lupus Nephritis
CN111689923B (zh) * 2019-03-12 2022-11-08 中国科学院上海药物研究所 一个具有逆转肿瘤多药耐药活性的环脂肽化合物、其制备方法及用途
BR112022007623A2 (pt) * 2019-10-23 2022-07-12 Chong Kun Dang Pharmaceutical Corp Composições para prevenir ou tratar doenças pulmonares obstrutivas crônicas (dpoc)
WO2022020245A1 (en) * 2020-07-20 2022-01-27 Insmed, Inc. Methods for extracting neutrophil serine proteases and treating dipeptidyl peptidase 1-mediated conditions
CA3190610A1 (en) 2020-08-26 2022-03-03 Haisco Pharmaceuticals Pte. Ltd. Nitrile derivative that acts as inhibitor of dipeptidyl peptidase 1 and use thereof
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
CN114159446A (zh) * 2020-09-11 2022-03-11 中国科学院上海营养与健康研究所 组织蛋白酶c抑制剂在治疗肿瘤转移中的应用
JP2023551488A (ja) * 2020-12-04 2023-12-08 瑞石生物医薬有限公司 カテプシンｃの小分子阻害剤及びその医薬的使用
CN114591315A (zh) * 2020-12-04 2022-06-07 瑞石生物医药有限公司 一种组织蛋白酶c小分子抑制剂
WO2022140516A1 (en) * 2020-12-22 2022-06-30 Insmed Incorporated Certain (25)-iv-[(ls')~ i-c yan0-2-phenylethyl·]- 1,4-oxazepane-2- carboxamides for treating behcet's disease
WO2022166721A1 (zh) * 2021-02-05 2022-08-11 南京明德新药研发有限公司 含1，4-氧杂氮杂环庚烷的并环类衍生物
EP4329767A4 (en) * 2021-04-29 2025-03-12 Insmed Incorporated CERTAIN (1-CYANO-2-PHENYLETHYL)-1,4-OXAZEPAN-2-CARBOXAMIDES FOR THE TREATMENT OF CYSTIC FIBROSIS
MX2024005126A (es) * 2021-10-29 2024-05-16 Insmed Inc Determinadas n-(1-ciano-2-feniletil)-1,4-oxazepano-2-carboxamidas para el tratamiento de la rinosinusitis cronica.
CN115925696A (zh) * 2021-10-29 2023-04-07 瑞石生物医药有限公司 一种1-氰基-2-苯基乙基甲酰胺衍生物及其用途
CN116332937A (zh) * 2021-12-23 2023-06-27 杭州邦顺制药有限公司 二肽基肽酶ⅰ抑制剂及其用途
JP2025504817A (ja) * 2022-01-11 2025-02-19 上海壹典医▲薬▼科技▲開▼▲発▼有限公司 ペプチジルニトリル化合物及びその使用
CA3244131A1 (en) * 2022-02-16 2023-08-24 Insmed Incorporated CERTAIN N-(1-CYANO-2-PHENYLETHYL)-1,4-OXAZEPANE-2-CARBOXAMIDES FOR THE TREATMENT OF HIDRADENITIS SUPPURATIVE
WO2023160541A1 (zh) 2022-02-22 2023-08-31 四川海思科制药有限公司 一种含氮杂环化合物的制备方法
EP4484424A1 (en) 2022-02-22 2025-01-01 Haisco Pharmaceuticals Pte. Ltd. Dipeptidyl peptidase 1 inhibitor polymorph, preparation method and use therefor
CN118660873A (zh) 2022-02-22 2024-09-17 西藏海思科制药有限公司 二肽基肽酶抑制剂化合物的盐及晶型
CN114644562B (zh) * 2022-04-29 2023-08-22 常州大学 具有红移荧光发射的有机小分子荧光化合物、制备方法及应用
EP4538277A4 (en) 2022-06-07 2025-10-08 Reistone Biopharma Company Ltd PHARMACEUTICALLY ACCEPTABLE SALT OF A BENZO[C]CHROMANE COMPOUND, POLYMORPHIC FORM AND USE OF A PHARMACEUTICALLY ACCEPTABLE SALT
CA3258114A1 (en) * 2022-06-07 2025-03-20 Reistone Biopharma Company Limited BENZO[C]CHROMANE COMPOUND POLYMORPH, ITS PREPARATION PROCESS AND ITS USE
KR20250022023A (ko) 2022-06-13 2025-02-14 알리벡시스 가부시키가이샤 아자사이클로알킬카보닐 환상 아민 화합물
WO2024008680A1 (en) 2022-07-06 2024-01-11 Chiesi Farmaceutici S.P.A. Azetidine derivatives and use thereof as dipeptidyl peptidase 1 inhibitors
WO2024081889A1 (en) 2022-10-14 2024-04-18 Genesis Therapeutics, Inc. 4h-pyrido[1,2-a]pyrimidin-4-one derivatives for treating cancer
WO2024088307A1 (zh) * 2022-10-26 2024-05-02 上海壹迪生物技术有限公司 一种新型肽基腈类化合物及其应用
CN115785083A (zh) * 2022-12-27 2023-03-14 瑞石生物医药有限公司 一种组织蛋白酶c小分子抑制剂及其制备方法
CN120584108A (zh) * 2023-01-06 2025-09-02 英斯梅德股份有限公司 新型可逆dpp1抑制剂及其用途
CN120693326A (zh) * 2023-02-15 2025-09-23 英斯梅德股份有限公司 某些1，4-氧杂氮杂环庚烷-2-甲酰胺作为dpp1抑制剂的用途
AU2024241242A1 (en) * 2023-03-23 2025-11-06 Haisco Pharmaceuticals Pte. Ltd. Pharmaceutical composition containing dipeptidyl peptidase small molecule inhibitor
WO2025059526A1 (en) * 2023-09-15 2025-03-20 Insmed Incorporated Dipeptidyl peptidase 1 inhibitors and uses thereof
USD1099133S1 (en) * 2024-02-01 2025-10-21 Apple Inc. Display screen or portion thereof showing a graphical user interface
WO2025214073A1 (en) * 2024-04-12 2025-10-16 Insmed Incorporated Dipeptidyl peptidase 1 inhibitors and uses thereof

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2782151B2 (ja) 1993-07-16 1998-07-30 博 吉田 衝撃吸収柵用の端ストッパ
US6297239B1 (en) 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
US6462076B2 (en) 2000-06-14 2002-10-08 Hoffmann-La Roche Inc. Beta-amino acid nitrile derivatives as cathepsin K inhibitors
DE60131423T2 (de) 2000-09-08 2009-03-19 Prozymex A/S Ratten-spezifische cathepsin, dipeptidyl peptidase i (dppi): kristallstruktur, hemmstoffe und deren anwendungen
TWI290919B (en) 2000-10-06 2007-12-11 Tanabe Seiyaku Co Nitrogen-containing five-membered ring compound, a pharmacologically permissible salt thereof and the method for producing the same
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
BR0214642A (pt) 2001-12-04 2004-11-03 Hoffmann La Roche Compostos, métodos para a preparação de um composto, composições farmacêuticas que compreendem o mesmo e método para o tratamento e/ou prevenção de enfermidades que estão associadas com protéases de cisteìna e utilização desses compostos
US20040253311A1 (en) 2002-12-18 2004-12-16 Roger Berlin Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihist amines
WO2004076434A1 (en) 2003-02-28 2004-09-10 Aic Dipeptidyl peptidase inhibitors
WO2004087153A2 (en) 2003-03-28 2004-10-14 Chiron Corporation Use of organic compounds for immunopotentiation
ATE399763T1 (de) 2003-05-30 2008-07-15 Prozymex As Proteasehemmer
WO2004110988A1 (en) 2003-06-18 2004-12-23 Prozymex A/S Protease inhibitors
MXPA06011463A (es) 2004-04-07 2007-04-25 Rinat Neuroscience Corp Metodos para tratar dolor por cancer de hueso al administrar un antagonista de factor de crecimiento de nervio.
EP1745292A2 (en) 2004-04-28 2007-01-24 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 1 (dpp1)
US7618981B2 (en) 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
SE0401657D0 (sv) 2004-06-24 2004-06-24 Astrazeneca Ab Chemical compounds
UA93353C2 (ru) 2004-06-29 2011-02-10 Никомед Данмарк Апс Производство фармацевтических композиций c быстрым высвобождением ha ochobe водонерастворимых лекарсвенных средств и фармацевтические композиции, полученные способом согласно изобретению
AU2005274852B2 (en) 2004-07-19 2011-12-08 The Johns Hopkins University FLT3 inhibitors for immune suppression
KR20070114753A (ko) 2005-02-18 2007-12-04 아브락시스 바이오사이언스 인크. 치료제의 조합 및 투여 방식, 및 조합 요법
JP2009500347A (ja) 2005-06-30 2009-01-08 アムジエン・インコーポレーテツド ビスアリールキナーゼ阻害剤及びこれらの炎症、血管新生及び癌の治療における使用
MX2009009540A (es) 2007-03-07 2009-09-16 Alantos Pharm Holding Inhibidores de metaloproteasa que contienen una porcion heterociclica.
TW200916447A (en) 2007-08-29 2009-04-16 Methylgene Inc Sirtuin inhibitors
BRPI0817311A2 (pt) 2007-09-25 2015-03-17 Novartis Ag Tratamento de doenças pulmonares com medicamentos em aerossol tais como a vancomicina
EP2231597A1 (en) * 2007-12-12 2010-09-29 AstraZeneca AB Peptidyl nitriles and use thereof as dipeptidyl peptidase i inhibitors
US9315449B2 (en) 2008-05-15 2016-04-19 Duke University Substituted pyrazoles as heat shock transcription factor activators
PE20100252A1 (es) 2008-06-06 2010-04-12 Boehringer Ingelheim Int Nuevas formulaciones farmaceuticas solidas que comprenden dimaleato de 4-[(3-cloro-4-fluorofenil) amino]-6-{[4-(n,n-dimetilamino)-1-oxo-2-buten-1-il] amino}-7-((s)-tetrahidrofuran-3-iloxi)-quinazolina
US9040508B2 (en) 2008-12-08 2015-05-26 Vm Pharma Llc Compositions of protein receptor tyrosine kinase inhibitors
RU2550133C2 (ru) 2009-04-01 2015-05-10 БИАЛ-ПОРТЕЛА энд КА., С.А. Фармацевтические составы, включающие производные нитрокатехола, и способы их получения
BRPI1015540A2 (pt) * 2009-05-07 2019-09-24 Astrazeneca Ab ''composto de 1-cianoetil-heterociclilcarboxamida substituídos 750''
WO2010142985A1 (en) * 2009-06-10 2010-12-16 Astrazeneca Ab Substituted n-[1-cyano-2-(phenyl)ethyl]piperidin-2-ylcarboxmide compounds 761
AR081760A1 (es) 2010-04-07 2012-10-17 Vertex Pharma Una composicion farmaceutica para administracion oral que comprende acido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropancarboxamido)-3-metilpiridin-2-il)benzoico, un metodo para producir la misma, una tableta y una forma unitaria de dosificacion oral que la comprende y el uso de la misma para la fabricacion de un medicamento
WO2011154677A1 (en) * 2010-06-09 2011-12-15 Astrazeneca Ab Substituted n-[1-cyano-2-(phenyl)ethyl] 1-aminocycloalk-1-ylcarboxamide compounds - 760
IT1404036B1 (it) 2010-12-17 2013-11-08 Oto Melara Spa Veicolo armato con struttura migliorata.
US8841463B2 (en) 2011-02-11 2014-09-23 Glaxosmithkline Intellectual Property Development Limited Cathepsin C inhibitors
WO2012119941A1 (en) 2011-03-04 2012-09-13 Prozymex A/S Peptidyl nitrilcompounds as peptidase inhibitors
US8999975B2 (en) 2011-09-19 2015-04-07 Boehringer Ingelheim International Gmbh Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C
US9120804B2 (en) 2012-02-21 2015-09-01 Merck Patent Gmbh 8-substituted 2-amino-[1,2,4] triazolo [1, 5-A] pyrazines as Syk tryrosine kinase inhibitors and GCN2 serin kinase inhibitors
PL2840083T3 (pl) 2012-04-17 2018-01-31 Astellas Pharma Inc Bicykliczny aromatyczny związek heterocykliczny zawierający azot
WO2014091443A1 (en) 2012-12-13 2014-06-19 Glaxo Group Limited Cathepsin c inhibitors for treating cystic fibrosis, non-cystic fibrosis bronchiectasis, and anca-associated vasculitis
EP2775304A1 (en) 2013-03-07 2014-09-10 Universitätsspital Basel Methods for detecting inflammatory disorder
EP2970252B1 (en) 2013-03-14 2020-06-03 Boehringer Ingelheim International GmbH Substituted 2-aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
PE20151727A1 (es) 2013-03-14 2015-12-17 Boehringer Ingelheim Int Acido 2-aza-biciclo[2.2.1]heptano-3-carboxilico (bencil-ciano-metil)-amidas sustituidas inhibidores de catepsina c
US8889708B2 (en) 2013-03-14 2014-11-18 Boehringer Ingelheim International Gmbh Substituted bicyclic 1-carboxylic-acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin C
WO2014140078A1 (en) 2013-03-14 2014-09-18 Boehringer Ingelheim International Gmbh Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (cyano-methyl)-amides inhibitors of cathepsin c
UY35400A (es) 2013-03-15 2014-10-31 Novartis Ag Compuestos y composiciones para el tratamiento de enfermedades parasitarias
EP2981247B1 (en) 2013-04-01 2023-06-07 Pulmatrix Operating Company, Inc. Tiotropium dry powders
WO2015027039A1 (en) 2013-08-22 2015-02-26 Emory University Devices and methods related to airway inflammation
WO2015032942A1 (en) 2013-09-09 2015-03-12 Prozymex A/S N-substituted 3,3'-(biphenyl-4,4'-diyl)bis-2-aminopropanenitriles as dppi inhibitors
EA029030B1 (ru) 2013-09-09 2018-01-31 Прозюмекс А/С Пептидилнитрильные соединения в качестве ингибиторов дипептидилпептидазы i
GB201400034D0 (en) 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
NO2699580T3 (enExample) 2014-01-24 2018-02-24
GB201402070D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
CA2943598C (en) 2014-04-10 2023-03-07 Novartis Ag S1p modulator immediate release dosage regimen
ES2926985T3 (es) 2014-05-15 2022-10-31 Insmed Inc Métodos para tratar infecciones pulmonares micobacterianas no tuberculosas
US9625460B2 (en) 2014-05-30 2017-04-18 Versitech Limited Methods and compositions for use of neutrophil elastase and proteinase 3 as diagnostic biomarkers
JP6529575B2 (ja) 2014-08-01 2019-06-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換オキセタンおよびそれらのカテプシンｃの阻害薬としての使用
EA031376B1 (ru) 2014-09-12 2018-12-28 Бёрингер Ингельхайм Интернациональ Гмбх Спироциклические ингибиторы катепсина с
BR112017009595A2 (pt) 2014-11-14 2017-12-19 Boehringer Ingelheim Int morfolina e 1,4-oxazepano amidas como agonistas do subtipo de receptor de somatostatina 4 (sstr4)
CA2978234C (en) 2015-03-05 2023-05-02 Prozymex A/S Peptidyl nitril compounds as dipeptidyl peptidase i inhibitors
KR20250107292A (ko) 2016-07-29 2025-07-11 인스메드 인코포레이티드 기관지확장증을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카르복스아미드
CA3089240A1 (en) * 2018-02-07 2019-08-15 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating anca associated vasculitides
KR102738945B1 (ko) 2018-03-01 2024-12-04 아스트라제네카 에이비이 (2s)-n-｛(1s)-1-시아노-2-[4-(3-메틸-2-옥소-2,3-디하이드로-1,3-벤족사졸-5-일)페닐]에틸｝-1,4-옥사제판-2-카복스아미드를 포함하는 약학 조성물
AU2019306532A1 (en) 2018-07-17 2021-03-04 Insmed Incorporated Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating Lupus Nephritis
WO2020018551A1 (en) 2018-07-17 2020-01-23 Insmed Incorporated Certain (2s)- n-[(1s)-1-cyano-2-phenylethyl]-1,4- oxazepane-2-carboxamides for treating inflammatory bowel disease
KR20220022115A (ko) 2019-04-17 2022-02-24 아조라 테라퓨틱스 인코포레이티드 염증성 피부 질환을 치료하기 위한 국소 조성물 및 방법
KR20220026538A (ko) 2019-06-05 2022-03-04 에모리 유니버시티 코로나바이러스 및 피코르나바이러스 감염 치료용 펩티도모방체
WO2022140516A1 (en) 2020-12-22 2022-06-30 Insmed Incorporated Certain (25)-iv-[(ls')~ i-c yan0-2-phenylethyl·]- 1,4-oxazepane-2- carboxamides for treating behcet's disease
CN112920124B (zh) 2021-01-29 2024-03-01 安徽医科大学 一种嘧啶-2,4-二胺类化合物及其制备方法与应用
EP4329767A4 (en) 2021-04-29 2025-03-12 Insmed Incorporated CERTAIN (1-CYANO-2-PHENYLETHYL)-1,4-OXAZEPAN-2-CARBOXAMIDES FOR THE TREATMENT OF CYSTIC FIBROSIS
WO2022232420A1 (en) 2021-04-29 2022-11-03 Insmed Incorporated Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating cancer
MX2024005126A (es) 2021-10-29 2024-05-16 Insmed Inc Determinadas n-(1-ciano-2-feniletil)-1,4-oxazepano-2-carboxamidas para el tratamiento de la rinosinusitis cronica.
CA3244131A1 (en) 2022-02-16 2023-08-24 Insmed Incorporated CERTAIN N-(1-CYANO-2-PHENYLETHYL)-1,4-OXAZEPANE-2-CARBOXAMIDES FOR THE TREATMENT OF HIDRADENITIS SUPPURATIVE

Also Published As

Publication number Publication date
SI3744714T1 (sl) 2025-05-30
US20230025351A1 (en) 2023-01-26
US20150210655A1 (en) 2015-07-30
HRP20250302T1 (hr) 2025-04-25
US20240132455A1 (en) 2024-04-25
BR112016016224A2 (enExample) 2017-08-08
TWI690517B (zh) 2020-04-11
US20230278969A1 (en) 2023-09-07
KR20160111470A (ko) 2016-09-26
AU2017200338B2 (en) 2018-03-01
SMT201800058T1 (it) 2018-03-08
US10669245B2 (en) 2020-06-02
EP3097086B1 (en) 2017-12-13
EP3744714B1 (en) 2025-01-15
MY194850A (en) 2022-12-19
JP2022096662A (ja) 2022-06-29
CY1120049T1 (el) 2018-12-12
KR102417684B1 (ko) 2022-07-05
ZA201605856B (en) 2020-02-26
RS56919B1 (sr) 2018-05-31
UY35963A (es) 2015-07-31
JP7336563B2 (ja) 2023-08-31
AU2018202956A1 (en) 2018-05-17
SMT202500137T1 (it) 2025-05-12
SG10201701056QA (en) 2017-03-30
DK3323814T3 (da) 2020-08-03
SMT202000433T1 (it) 2020-09-10
US20230069044A1 (en) 2023-03-02
US11655222B2 (en) 2023-05-23
US12054465B2 (en) 2024-08-06
EP3323814A1 (en) 2018-05-23
AU2015208932A1 (en) 2016-07-28
EP4548972A3 (en) 2025-06-25
SI3097086T1 (en) 2018-04-30
US20200017455A1 (en) 2020-01-16
US9522894B2 (en) 2016-12-20
CA2935625A1 (en) 2015-07-30
NZ734768A (en) 2022-09-30
HUE070606T2 (hu) 2025-06-28
DK3097086T3 (en) 2018-02-05
PL3323814T3 (pl) 2020-10-19
AU2017200338A1 (en) 2017-02-02
EP3744714A1 (en) 2020-12-02
CN105980367B (zh) 2019-08-23
JP2025157389A (ja) 2025-10-15
PT3744714T (pt) 2025-04-07
HK1225730B (en) 2017-09-15
US11655221B2 (en) 2023-05-23
US20230116721A1 (en) 2023-04-13
JP7628587B2 (ja) 2025-02-10
PT3323814T (pt) 2020-08-05
ZA201800431B (en) 2019-09-25
LT3744714T (lt) 2025-04-10
HUE052421T2 (hu) 2021-04-28
MX2016009349A (es) 2016-10-13
US10287258B2 (en) 2019-05-14
HRP20201147T1 (hr) 2020-12-11
IL265611A (en) 2019-05-30
PT3097086T (pt) 2018-02-21
US11773069B2 (en) 2023-10-03
JP7714823B2 (ja) 2025-07-29
HRP20180116T1 (hr) 2018-03-23
US11680049B2 (en) 2023-06-20
EP3097086A1 (en) 2016-11-30
US11655223B2 (en) 2023-05-23
AU2019202675B2 (en) 2020-05-28
PE20161218A1 (es) 2016-11-27
US11814359B2 (en) 2023-11-14
US11673871B2 (en) 2023-06-13
DK3744714T3 (da) 2025-04-07
DOP2016000175A (es) 2016-08-15
US20230085620A1 (en) 2023-03-23
SG11201606052TA (en) 2016-08-30
US11673872B2 (en) 2023-06-13
US11655224B2 (en) 2023-05-23
ES3018635T3 (es) 2025-05-16
EA032794B1 (ru) 2019-07-31
LT3097086T (lt) 2018-02-26
US20230033573A1 (en) 2023-02-02
US20200247765A1 (en) 2020-08-06
EA201691375A1 (ru) 2017-01-30
US20230250071A1 (en) 2023-08-10
AU2015208932B8 (en) 2017-03-09
WO2015110826A1 (en) 2015-07-30
JP7157791B2 (ja) 2022-10-20
LT3323814T (lt) 2020-10-26
SI3323814T1 (sl) 2020-10-30
US20210238152A1 (en) 2021-08-05
PL3097086T3 (pl) 2018-04-30
US20180251436A1 (en) 2018-09-06
AU2019202675A1 (en) 2019-05-16
BR112016016224B1 (pt) 2023-02-23
AU2015208932A8 (en) 2017-03-09
US20230028726A1 (en) 2023-01-26
JP2017503832A (ja) 2017-02-02
CR20160327A (es) 2016-10-20
EP3323814B1 (en) 2020-05-13
ES2658516T3 (es) 2018-03-12
HK1255870A1 (en) 2019-08-30
CA2935625C (en) 2022-10-18
CY1123391T1 (el) 2021-12-31
RS66709B1 (sr) 2025-05-30
PH12016501439B1 (en) 2017-02-06
JP2019070029A (ja) 2019-05-09
US20230062646A1 (en) 2023-03-02
US11117874B2 (en) 2021-09-14
CN105980367A (zh) 2016-09-28
PL3744714T3 (pl) 2025-09-08
NZ722063A (en) 2017-09-29
JP6804570B2 (ja) 2020-12-23
MX368840B (es) 2019-10-18
US9815805B2 (en) 2017-11-14
JP2021046423A (ja) 2021-03-25
AU2015208932B2 (en) 2017-02-16
HUE038274T2 (hu) 2018-10-29
IL246614B (en) 2018-02-28
JP6469711B2 (ja) 2019-02-13
TW201612167A (en) 2016-04-01
AU2015208932C1 (en) 2017-05-25
CN110483492A (zh) 2019-11-22
NO2699580T3 (enExample) 2018-02-24
RS60639B1 (sr) 2020-09-30
CL2016001889A1 (es) 2016-12-09
ES2808060T3 (es) 2021-02-25
FI3744714T3 (fi) 2025-04-01
US20230115170A1 (en) 2023-04-13
CN110483492B (zh) 2023-07-21
AR099177A1 (es) 2016-07-06
JP2025072423A (ja) 2025-05-09
US20170057938A1 (en) 2017-03-02
IL252836A0 (en) 2017-08-31
JP2023156479A (ja) 2023-10-24
US11667615B2 (en) 2023-06-06
US20240336582A1 (en) 2024-10-10
AU2018202956B2 (en) 2019-05-09
EP4548972A2 (en) 2025-05-07
PH12016501439A1 (en) 2017-02-06

Similar Documents

Publication Publication Date Title
IL265611A (en) (S2)–N–[S)1)–1–cyano–2–phenylethanyl]–1,4–oxazaphene–2–carboxamides as dipeptidyl peptidase 1 inhibitors
IL277167B (en) Cyclopropylamines as lsd1 inhibitors
IL277299B (en) Cyclopropylamines as lsd1 inhibitors
IL246785A0 (en) Benzimidazole-2-amines as midh1 inhibitors
DK3265452T3 (en) Peptidyl nitril compounds as dipeptidyl peptidase i inhibitors
IL256347A (en) New thrombin inhibitors